Company profile
Centre For Process Innovation Limited
Let's innovate together | CPI
CPI is an innovation catalyst for the adoption of advanced tech and manufacturing solutions that benefit people, places, and our planet.
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Group
Accounts PDF pendingAA | Transaction MzQ0MTA5OTYyNGFkaXF6a2N4 | Paper/PDF filed
Published 30 Oct 2024 07:17
Appoint Person Secretary Company With Name Date
OfficersAP03 | Transaction MzQzNzkxMzg5MGFkaXF6a2N4
Published 01 Oct 2024 07:33
Termination Secretary Company With Name Termination Date
OfficersTM02 | Transaction MzQzNzY3NDY4NmFkaXF6a2N4
Published 30 Sep 2024 07:49
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Enhancing Enzyme Quality and Yield to Unlock Sustainable Biocatalytic Nitration
1 Feb 2026 to 31 Jul 2026
Our project, Novel Biocatalysts for Sustainable Manufacture of Pharmaceuticals, is developing a greener, safer way to produce important pharmaceutical chemicals. Traditional chemical processes for adding nitro groups to molecules require harsh conditions and generate hazardous waste. We are replacing these methods with enzymes called nitrating cytochrome ...
Enhanced assays for low dose, high potency RNA-LNP medicines
1 Feb 2026 to 31 Jul 2026
Self-amplifying RNA (saRNA) is a new class of therapeutic RNA which offers major sustainability benefits compared with conventional RNA, including higher potency and substantially reduced dose requirements. This supports greener manufacturing and lowers resource use across production, storage, and administration. However, these same properties mean that a...
Advanced Medicine Manufacturing Sensor
1 Feb 2026 to 31 Jul 2026
As AMM therapies become more mainstream, conventional measurement and analysis technologies are increasingly pushed beyond their traditional usage boundaries. LiquiSensor is an emerging technology with strong potential for pharmaceutical process monitoring, but its current implementation presents challenges in this new field. Personalised medicine relies ...
Verinnogen Ltd
1 Jan 2026 to 31 Mar 2026
HLA Start and Scale RTO Pilot
1 Nov 2025 to 31 Oct 2026
Smart Personalised Healthcare: Evaluation, Response and Engagement (SPHERE)
1 Oct 2025 to 31 Mar 2026
The **S**mart **P**ersonalised **H**ealthcare: **E**valuation, **R**esponse and **E**ngagement (**SPHERE**) is a UK-wide collaboration led by the Catapult Network that aims to make personalised and preventative healthcare a practical reality for everyone. The vision: _"A healthcare system where every individual receives the right diagnosis, the right trea...
Cotton Mouton Diagnostics
1 May 2025 to 31 Oct 2025
pilot Centre of Expertise for Advanced Materials and Sustainability
1 Apr 2025 to 31 Mar 2026
The pilot Centre of Expertise for Advanced Materials and Sustainability (CEAMS) (formerly Sustainable Materials Translational Research Centre (SMTRC)) is a collaboration funded by the Innovation Accelerator (IA) programme (2023-2025) via Greater Manchester Combined Authority (GMCA) and Innovate UK (IUK). It is led by major regional and national stakeholde...
Novel Biocatalysts for Sustainable Manufacture of Pharmaceuticals
1 Mar 2025 to 28 Feb 2027
ErebaGen harnesses chemistry from Nature and its project aims to transform hazardous chemical manufacture through the use of sustainable biological processes. The innovation focus and need is aromatic nitration, a critical chemical step in production of numerous pharmaceutical intermediates. This reaction proceeds rapidly, generates heat, can get out of c...
Bioprocess development for sustainable production of mycosporines
1 Mar 2025 to 28 Feb 2026
Traditional sunscreen formulations are highly effective for the prevention of skin cancer (the 5th most common cancer in the UK). However, the UV protective active ingredients used in their formulations have a number of health and environmental issues. Some sunscreen actives can absorb into the skin, leading to hormone disruption and skin sensitivity issu...
Antibodies Unchained: Cold-Chain Free and Patient-Friendly therapies
1 Feb 2025 to 31 Jan 2027
Currently antibody medicines require ultra-cold-chain during production and storage to prevent spoiling due to aggregation at the molecular level, which can occur at any stage from factory to patient. This project uses game-changing, proprietary Ensilication technology to remove this cold-chain dependence in the manufacturing and supply of antibody treatm...
The Bio Revolution for weight-loss drugs: Enabling biomanufacturing of blockbuster GLP-1 agonists
1 Feb 2025 to 31 Jan 2027
Therapeutic peptides are set to dominate the top-selling drugs list over the next decade. Incretin mimetics such as Semaglutide (brand names Ozempic/Wegovy/Rybelsus) and Tirzepatide (brand names Zepbound/Mounjaro) are projected to make up 5 of the top 10 selling drugs by 2030, with combined sales of $116Bn. Each of these active pharmaceutical ingredients ...